(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Figure out how to Arrange a Fair Settlement with the Assistance of a Fender bender Legal counselor - 2Gen Z workplace stereotypes were TV’s favorite punchline in 2025
- 3Fundamental Home Items Each Animal person Needs
- 47 Fun Plans to Make Film Evenings Seriously Invigorating (You'll Cherish #5!)
- 5Carrying on with a Sans plastic Way of life: Individual Examinations in Maintainability
- 2024 Moving Styles for Kitchen Redesigns
- Israel’s mixed messaging on Christmas draws controversy
- 9 African migrants died in freezing temperatures near Morocco-Algeria border
- The Iran war’s energy security legacy
- Elanco's drug gets emergency nod to treat deadly flesh-eating parasite in cats
- New hybrid mpox strain discovered in UK after US reports local spread
- Syria rejects forced deportations from Germany amid migration debate
- I’m a dad to an autistic child. Here’s how you can make the holidays easier for all of us.
- Vote In favor of Your Favored Pizza Cover
